NCT06287528

A Phase I Trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells That Constitutively Secrete Interleukin 18 (19-28z/IL-18) in Patients With Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Study Summary

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy that participants will receive during the study. Making the participants' study therapy will take about 2-4 weeks.

Want to learn more about this trial?

Request More Info

Interventions

19-28z/IL-18 CAR T cellsBIOLOGICAL
19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL

Study Locations

FacilityCityStateCountry
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)Basking RidgeNew JerseyUnited States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)MiddletownNew JerseyUnited States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)MontvaleNew JerseyUnited States
Memorial Sloan Kettering Cancer Suffolk-Commack (Limited Protocol Activities)CommackNew YorkUnited States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)HarrisonNew YorkUnited States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew YorkUnited States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)UniondaleNew YorkUnited States

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026